Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 13/20 | 0.54 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30193410 | 1.00 | PTK6 (0.54) | PTK6MAPKAPK5SYKEGFRTTK | |
| SCHEMBL30171795 | 0.92 | PTK6 (0.53) | PTK6MAPKAPK5SYKTTKLCK | |
| SCHEMBL22124031 | 0.92 | PTK6 (0.53) | PTK6MAPKAPK5SYKTTKLCK | |
| SCHEMBL25170256 | 0.91 | MAPKAPK5 (0.48) | PTK6MAPKAPK5SYKTTKAURKB | |
| SCHEMBL30385742 | 0.91 | MAPKAPK5 (0.48) | PTK6MAPKAPK5SYKTTKAURKB | |
| SCHEMBL22123546 | 0.90 | MAPKAPK5 (0.47) | PTK6MAPKAPK5SYKTTKAURKB | |
| SCHEMBL30386489 | 0.90 | MAPKAPK5 (0.47) | PTK6MAPKAPK5SYKTTKAURKB | |
| SCHEMBL24112094 | 0.88 | PTK6 (0.62) | PTK6MAPKAPK5LCKAURKB | |
| Hydrochloric Acid SCHEMBL22124336 | 0.87 | PTK6 (0.72) | PTK6LCKAURKB | |
| Hydrochloric Acid SCHEMBL30385867 | 0.87 | PTK6 (0.72) | PTK6LCKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3897840-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898629-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898630-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897839-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020126956-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127075-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126954-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126952-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | PTK6 925/4885MAPKAPK5 508/4885SYK 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.